Published in Histopathology on June 01, 2010
Genetic variation in genes involved in hormones, inflammation and energetic factors and breast cancer risk in an admixed population. Carcinogenesis (2012) 1.40
Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance. J Clin Invest (2013) 1.19
Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res Treat (2012) 1.10
Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas. Int J Clin Exp Pathol (2012) 0.92
Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma. Oncol Lett (2012) 0.87
Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer. BMC Cancer (2014) 0.84
The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo. Breast Cancer Res (2014) 0.76
P-mTOR Expression and Implication in Breast Carcinoma: A Systematic Review and Meta-Analysis. PLoS One (2017) 0.75
Olive Oil-derived Oleocanthal as Potent Inhibitor of Mammalian Target of Rapamycin: Biological Evaluation and Molecular Modeling Studies. Phytother Res (2015) 0.75
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol (2005) 4.69
Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer (2010) 1.71
Statin treated patients have reduced intraplaque angiogenesis in carotid endarterectomy specimens. Atherosclerosis (2007) 1.60
The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol (2008) 1.59
Actinomycosis of the appendix and pelvis: a case report. J Reprod Med (2008) 1.58
Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum (2010) 1.52
Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Cancer (2008) 1.43
Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res (2008) 1.26
Embryonal rhabdomyosarcoma of the uterine cervix. Clin Transl Oncol (2009) 1.12
Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncol (2005) 1.12
Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. Mod Pathol (2006) 1.12
A mixability theory for the role of sex in evolution. Proc Natl Acad Sci U S A (2008) 1.08
Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer (2011) 1.06
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Res Treat (2011) 1.05
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat (2012) 1.01
Application of alpha-smooth muscle actin and c-kit in the differential diagnosis of adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Oral Oncol (2006) 1.01
Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. Ren Fail (2010) 1.00
The expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and angiogenesis markers in hyperplastic and malignant prostate tissue. Anticancer Res (2006) 1.00
Muscle impairment occurs rapidly and precedes inflammatory cell accumulation after mechanical loading. Am J Physiol Regul Integr Comp Physiol (2002) 0.97
Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome. Breast Cancer Res (2006) 0.97
Granulosa cell tumor of the ovary: tumor review. Integr Cancer Ther (2008) 0.96
The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin. Nephrol Dial Transplant (2010) 0.96
Treatment of early uterine sarcomas: disentangling adjuvant modalities. World J Surg Oncol (2009) 0.95
Inflammatory cells in rat skeletal muscle are elevated after electrically stimulated contractions. J Appl Physiol (1985) (2002) 0.95
A computational model of cell migration coupling the growth of focal adhesions with oscillatory cell protrusions. J Theor Biol (2008) 0.94
Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. Molecules (2009) 0.93
Sex, mixability, and modularity. Proc Natl Acad Sci U S A (2010) 0.92
The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma. Gynecol Oncol (2006) 0.92
Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid. Transl Res (2010) 0.92
Downhill running in rats: influence on neutrophils, macrophages, and MyoD+ cells in skeletal muscle. Eur J Appl Physiol (2003) 0.91
Potential role of the alcohol and smoking in the squamous cell carcinoma of the head and neck: review of the current literature and new perspectives. Asian Pac J Cancer Prev (2011) 0.91
All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev (2010) 0.91
Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev (2011) 0.91
Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma (2003) 0.91
Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology (2011) 0.91
Imaging in situ breast carcinoma (with or without an invasive component) with technetium-99m pentavalent dimercaptosuccinic acid and technetium-99m 2-methoxy isobutyl isonitrile scintimammography. Breast Cancer Res (2004) 0.90
Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer. Histopathology (2012) 0.89
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. Anticancer Res (2011) 0.89
Effect of the different phosphorylated Smad2 protein localizations on the invasive breast carcinoma phenotype. APMIS (2007) 0.89
Clinicopathologic predictors of death and ESRD in patients with pauci-immune necrotizing glomerulonephritis. Am J Kidney Dis (2003) 0.87
Ibuprofen and acetaminophen: effect on muscle inflammation after eccentric exercise. Med Sci Sports Exerc (2003) 0.86
Evaluation of the vascular endothelial growth factor (VEGF)-C role in urothelial carcinomas of the bladder. Anticancer Res (2006) 0.86
Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer (2005) 0.86
Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. Anticancer Res (2007) 0.85
Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer. Biomark Insights (2008) 0.85
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat (2005) 0.85
A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer. Int J Gastrointest Cancer (2005) 0.85
Basaloid squamous cell carcinoma versus basal cell adenocarcinoma of the oral cavity. Pathology (2005) 0.84
Detection of human papillomavirus (HPV) DNA prevalence and p53 codon 72 (Arg72Pro) polymorphism in prostate cancer in a Greek group of patients. Tumour Biol (2014) 0.84
Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome. J Clin Oncol (2005) 0.84
Cyclin D1 in invasive breast carcinoma: favourable prognostic significance in unselected patients and within subgroups with an aggressive phenotype. Histopathology (2012) 0.83
Nuclear hTERT immunohistochemical expression is associated with survival of patients with urothelial bladder cancer. Anticancer Res (2005) 0.83
Mechanical loading and injury induce human myotubes to release neutrophil chemoattractants. Am J Physiol Cell Physiol (2004) 0.83
Effectiveness of an intensive nutritional intervention in patients with type 2 diabetes mellitus: results from a pilot study. Rev Diabet Stud (2008) 0.83
Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol (2004) 0.83
Immunohistochemical expression of P15 (INK4B) and SMAD4 in advanced gastric cancer. Anticancer Res (2008) 0.82
An immunohistochemical evaluation of the proteins Wnt1 and glycogen synthase kinase (GSK)-3β in invasive breast carcinomas. Histopathology (2013) 0.82
Biopsy-proven resolution of renal light-chain deposition disease after autologous stem cell transplantation. Nephrol Dial Transplant (2010) 0.82
Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications. Urol Res (2002) 0.82
Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. PLoS One (2013) 0.81
KISS1 expression in colorectal cancer. APMIS (2013) 0.81
Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas. Clin Cancer Res (2003) 0.81
Immunohistochemical detection of the expression of the cell adhesion molecules E-cadherin, desmoglein-2, beta4-integrin, ICAM-1 and HCAM (CD44s) in Warthin's tumour of the parotid gland. Oral Oncol (2005) 0.81
Extra copies of chromosomes 16 and X in invasive breast carcinomas are related to aggressive phenotype and poor prognosis. J Clin Pathol (2007) 0.80
Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. PLoS One (2013) 0.80
Local treatment of experimental Pseudomonas aeruginosa osteomyelitis with a biodegradable dilactide polymer releasing ciprofloxacin. Antimicrob Agents Chemother (2008) 0.80
Differential effect of the expression of TGF-β pathway inhibitors, Smad-7 and Ski, on invasive breast carcinomas: relation to biologic behavior. APMIS (2011) 0.80
The key role of bisphosphonates in the supportive care of cancer patients. Anticancer Res (2014) 0.80
Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience. Oncology (2006) 0.80
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. Breast Cancer Res Treat (2014) 0.80
Serum lipid profile and hepatic steatosis of adult beta-thalassaemia patients with chronic HCV infection. Eur J Gastroenterol Hepatol (2005) 0.79
High dose therapy with autologous stem cell transplantation for solitary bone plasmacytoma complicated by local relapse or isolated distant recurrence. Leuk Lymphoma (2003) 0.78
Rapamycin induced ultrastructural and molecular alterations in glomerular podocytes in healthy mice. Nephrol Dial Transplant (2012) 0.78
Decreased Hsp90 expression in infiltrative lobular carcinoma: an immunohistochemical study. BMC Cancer (2010) 0.77
Rapamycin for focal segmental glomerulosclerosis: a report of 3 cases. Am J Kidney Dis (2009) 0.77
Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. BMC Cancer (2006) 0.77
Immunohistochemical evaluation of phosphorylated SMAD2/SMAD3 and the co-activator P300 in human glomerulonephritis: correlation with renal injury. J Cell Mol Med (2006) 0.77
Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer. Med Oncol (2006) 0.77
Nestin involvement in tissue injury and cancer--a potential tumor marker? Cell Oncol (Dordr) (2014) 0.77
Histological deterioration of obesity-related glomerulopathy despite the loss of proteinuria with weight reduction. Pediatr Nephrol (2010) 0.77
Rapamycin ameliorates proteinuria and restores nephrin and podocin expression in experimental membranous nephropathy. Clin Dev Immunol (2013) 0.77
The potential role of Calcitonin Gene-Related Peptide (CGRP) in breast carcinogenesis and its correlation with 99mTc-(V)DMSA scintimammography. Am J Clin Oncol (2007) 0.77
The concurrence of microalbuminuria and retinopathy with cardiovascular risk factors; reliable predictors of asymptomatic coronary artery disease in type 2 diabetes. Hormones (Athens) (2006) 0.77
Thrombotic microangiopathy in a patient with Sezary syndrome treated with interferon-alpha. Nephrol Dial Transplant (2004) 0.77